Dec 8, 2023
The FDA approves Casgevy for sickle cell disease in patients aged 12 and older. It is the first FDA-approved treatment to use CRISPR-Cas9 genome editing.
An experimental gene-editing method reaches an approved clinical application. Approval scope, treatment access and long-term follow-up remain part of the story.